Taking Wegovy with hyperthyroidism: what the evidence says

What the licensed guidance actually says about thyroid conditions and semaglutide

The Wegovy Summary of Product Characteristics, published on the electronic Medicines Compendium, does not list hyperthyroidism as an absolute contraindication. That is not the same as saying it is straightforwardly safe. The SmPC does carry a prominent precaution regarding thyroid C-cell tumours: in rodent studies, semaglutide was associated with thyroid C-cell changes, and while no equivalent signal has been confirmed in humans, the medicine is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Hyperthyroidism is a different condition, caused by excess thyroid hormone production rather than a tumour, but the overlap in territory means any prescriber will want a clear picture of your thyroid diagnosis before proceeding.

The NHS medicines page for semaglutide advises telling your doctor about all existing health conditions before starting, with thyroid disease explicitly mentioned as something to disclose. That framing is deliberate: it is not a refusal, it is a flag for clinical judgement. For people with hyperthyroidism that is currently uncontrolled or newly diagnosed, most prescribers would want the condition stabilised before considering whether Wegovy is appropriate. For those whose thyroid function has been well-managed for some time, the conversation is different, and more nuanced.

If you are exploring treatment options, our overview of Wegovy covers how the medicine works and what the UK licence covers.

Why an overactive thyroid changes the risk calculation

Hyperthyroidism already does things to the body that overlap with GLP-1 side effects in ways that matter clinically. An overactive thyroid raises resting heart rate, can cause palpitations, and often produces unintended weight loss on its own. Nausea and gastrointestinal discomfort are also common in hyperthyroidism. Wegovy's most frequent side effects are gastrointestinal (nausea, vomiting, diarrhoea) and are typically most pronounced when starting treatment or after a dose increase, as documented in the STEP 1 trial published in the New England Journal of Medicine. Starting both sources of GI disruption simultaneously, or adding them together during an already-symptomatic thyroid flare, creates a picture that is genuinely harder to manage.

There is also a monitoring consideration. Hyperthyroidism accelerates metabolism. If thyroid function is still changing (because treatment for the condition is being initiated or adjusted) body weight fluctuates independently of any weight-management medicine. That makes it harder for a prescriber to interpret how a patient is responding to Wegovy, and harder to know whether a dose increase is safe or appropriate.

None of this makes Wegovy impossible for someone with a thyroid history. It makes clinical review more thorough. People who have had hyperthyroidism treated successfully, whether by medication, radioiodine or surgery, and whose thyroid levels are now within a stable normal range, are in a meaningfully different position from someone mid-treatment. A prescriber needs that information. If you have an underactive thyroid rather than an overactive one, you can read about whether it is safe to take Wegovy with hypothyroidism, since some patients move between diagnoses over time, and the considerations differ. You might also find it useful to read about how Wegovy interacts with hypothyroidism, since some patients move between diagnoses over time.

What is still uncertain, and who should be involved in your decision

It is honest to say the clinical literature does not yet contain large, dedicated studies of GLP-1 receptor agonists in patients with active hyperthyroidism as a defined subgroup. The STEP programme enrolled adults with obesity or overweight and at least one weight-related condition, but thyroid disease status was not a primary stratification variable. That means prescribers are working from pharmacological principles, SmPC guidance, and individual clinical judgement rather than from a head-to-head hyperthyroidism trial.

If you are under the care of an endocrinologist or specialist for your thyroid condition, involving them in this decision is not just good practice, it is the kind of joined-up care that makes a material difference. Your GP or specialist can advise on whether your thyroid function is stable enough to consider weight management treatment, and which approach fits your overall picture. The NHS England guidance on weight-management injections is explicit that these medicines work best alongside broader lifestyle and clinical support.

We appreciate that sitting with this uncertainty is frustrating, especially if excess weight is affecting your health and you have already spent time managing a thyroid condition. That dual burden is real, and it deserves a proper clinical conversation rather than a yes or no from a website. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber who reads your answers the same day, a real clinician, not automated decision-making. If your situation is complex, they will say so, and they will explain why. For further detail on how we handle complex medical histories, including questions such as whether you can take Wegovy with type 2 diabetes or whether Wegovy is suitable alongside heart failure, our about us page sets out how our clinical process works. If you are ready to explore whether Wegovy is suitable for you, start your free consultation and a prescriber will review your full picture.